MediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average – What’s Next?

MediWound Ltd. (NASDAQ:MDWD) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $16.99 and traded as high as $17.55. MediWound shares last traded at $17.44, with a volume of 97,816 shares traded.

Analysts Set New Price Targets

MDWD has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Wall Street Zen downgraded MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MediWound presently has a consensus rating of “Hold” and a consensus price target of $35.00.

MediWound Stock Up 1.0%

The company has a 50 day moving average of $16.99 and a 200 day moving average of $17.70. The firm has a market cap of $224.10 million, a price-to-earnings ratio of -8.30 and a beta of 0.21.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) EPS for the quarter. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The business had revenue of $1.87 million during the quarter. As a group, equities research analysts expect that MediWound Ltd. will post -2.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

Institutional investors have recently made changes to their positions in the stock. Meitav Investment House Ltd. grew its holdings in shares of MediWound by 825.7% during the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock valued at $5,241,000 after purchasing an additional 260,116 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of MediWound during the third quarter valued at approximately $1,042,000. Menora Mivtachim Holdings LTD. grew its holdings in shares of MediWound by 348.8% during the third quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock valued at $1,415,000 after purchasing an additional 61,039 shares during the last quarter. Rosalind Advisors Inc. grew its holdings in shares of MediWound by 84.0% during the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after purchasing an additional 341,993 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after purchasing an additional 68,756 shares during the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.